世界の加齢黄斑変性症（ARMD）治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z0160 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、90ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥553,800 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥830,700 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,107,600 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、加齢黄斑変性症（ARMD）治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（抗VEGF薬、感光性薬、その他）、用途別市場規模（滲出性ARMD、萎縮性ARMD）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・加齢黄斑変性症（ARMD）治療薬の市場動向 ・企業の競争状況、市場シェア ・加齢黄斑変性症（ARMD）治療薬の種類別市場規模（抗VEGF薬、感光性薬、その他） ・加齢黄斑変性症（ARMD）治療薬の用途別市場規模（滲出性ARMD、萎縮性ARMD） ・加齢黄斑変性症（ARMD）治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・加齢黄斑変性症（ARMD）治療薬のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・加齢黄斑変性症（ARMD）治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・加齢黄斑変性症（ARMD）治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・加齢黄斑変性症（ARMD）治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Roche、Regeneron Pharmaceuticals、Bayer、Santen Oy、Kanghong Pharmaceuticals、Novartis、Eli Lilly and Company、TRACON Pharmaceuticals、Pfizer、GSK、BIOCAD） ・結論

Market Analysis and Insights: Global Age-relatedMacularDegeneration (ARMD) Drugs Market
The global Age-relatedMacularDegeneration (ARMD) Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Age-relatedMacularDegeneration (ARMD) Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Age-relatedMacularDegeneration (ARMD) Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Age-relatedMacularDegeneration (ARMD) Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Age-relatedMacularDegeneration (ARMD) Drugs market.

Global Age-relatedMacularDegeneration (ARMD) Drugs Scope and Market Size
Age-relatedMacularDegeneration (ARMD) Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Age-relatedMacularDegeneration (ARMD) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Anti VEGF Drugs
Photosensitive Drugs
Others

Segment by Application
Exudative ARMD
Atrophy ARMD

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Roche
Regeneron Pharmaceuticals
Bayer
Santen Oy
Kanghong Pharmaceuticals
Novartis
Eli Lilly and Company
TRACON Pharmaceuticals
Pfizer

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Anti VEGF Drugs
1.2.3 Photosensitive Drugs
1.2.4 Others
1.3 Market by Application
1.3.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Exudative ARMD
1.3.3 Atrophy ARMD
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Perspective (2016-2027)
2.2 Age-relatedMacularDegeneration (ARMD) Drugs Growth Trends by Regions
2.2.1 Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Age-relatedMacularDegeneration (ARMD) Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Age-relatedMacularDegeneration (ARMD) Drugs Industry Dynamic
2.3.1 Age-relatedMacularDegeneration (ARMD) Drugs Market Trends
2.3.2 Age-relatedMacularDegeneration (ARMD) Drugs Market Drivers
2.3.3 Age-relatedMacularDegeneration (ARMD) Drugs Market Challenges
2.3.4 Age-relatedMacularDegeneration (ARMD) Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Age-relatedMacularDegeneration (ARMD) Drugs Players by Revenue
3.1.1 Global Top Age-relatedMacularDegeneration (ARMD) Drugs Players by Revenue (2016-2021)
3.1.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Age-relatedMacularDegeneration (ARMD) Drugs Revenue
3.4 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Concentration Ratio
3.4.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Age-relatedMacularDegeneration (ARMD) Drugs Revenue in 2020
3.5 Age-relatedMacularDegeneration (ARMD) Drugs Key Players Head office and Area Served
3.6 Key Players Age-relatedMacularDegeneration (ARMD) Drugs Product Solution and Service
3.7 Date of Enter into Age-relatedMacularDegeneration (ARMD) Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Age-relatedMacularDegeneration (ARMD) Drugs Breakdown Data by Type
4.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Historic Market Size by Type (2016-2021)
4.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Type (2022-2027)

5 Age-relatedMacularDegeneration (ARMD) Drugs Breakdown Data by Application
5.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Historic Market Size by Application (2016-2021)
5.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2016-2027)
6.2 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type
6.2.1 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2016-2021)
6.2.2 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2022-2027)
6.2.3 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2016-2027)
6.3 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application
6.3.1 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2016-2021)
6.3.2 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2022-2027)
6.3.3 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2016-2027)
6.4 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country
6.4.1 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2016-2021)
6.4.2 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2016-2027)
7.2 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type
7.2.1 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2016-2021)
7.2.2 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2022-2027)
7.2.3 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2016-2027)
7.3 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application
7.3.1 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2016-2021)
7.3.2 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2022-2027)
7.3.3 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2016-2027)
7.4 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country
7.4.1 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2016-2021)
7.4.2 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2016-2027)
8.2 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type
8.2.1 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application
8.3.1 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region
8.4.1 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2016-2027)
9.2 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type
9.2.1 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2016-2027)
9.3 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application
9.3.1 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2016-2027)
9.4 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country
9.4.1 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2016-2027)
10.2 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type
10.2.1 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application
10.3.1 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country
10.4.1 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.1.4 Roche Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021)
11.1.5 Roche Recent Development
11.2 Regeneron Pharmaceuticals
11.2.1 Regeneron Pharmaceuticals Company Details
11.2.2 Regeneron Pharmaceuticals Business Overview
11.2.3 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.2.4 Regeneron Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021)
11.2.5 Regeneron Pharmaceuticals Recent Development
11.3 Bayer
11.3.1 Bayer Company Details
11.3.2 Bayer Business Overview
11.3.3 Bayer Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.3.4 Bayer Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021)
11.3.5 Bayer Recent Development
11.4 Santen Oy
11.4.1 Santen Oy Company Details
11.4.2 Santen Oy Business Overview
11.4.3 Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.4.4 Santen Oy Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021)
11.4.5 Santen Oy Recent Development
11.5 Kanghong Pharmaceuticals
11.5.1 Kanghong Pharmaceuticals Company Details
11.5.2 Kanghong Pharmaceuticals Business Overview
11.5.3 Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.5.4 Kanghong Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021)
11.5.5 Kanghong Pharmaceuticals Recent Development
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview
11.6.3 Novartis Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.6.4 Novartis Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021)
11.6.5 Novartis Recent Development
11.7 Eli Lilly and Company
11.7.1 Eli Lilly and Company Company Details
11.7.2 Eli Lilly and Company Business Overview
11.7.3 Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.7.4 Eli Lilly and Company Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021)
11.7.5 Eli Lilly and Company Recent Development
11.8 TRACON Pharmaceuticals
11.8.1 TRACON Pharmaceuticals Company Details
11.8.2 TRACON Pharmaceuticals Business Overview
11.8.3 TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.8.4 TRACON Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021)
11.8.5 TRACON Pharmaceuticals Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.9.4 Pfizer Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021)
11.9.5 Pfizer Recent Development
11.10 GSK
11.10.1 GSK Company Details
11.10.2 GSK Business Overview
11.10.3 GSK Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.10.4 GSK Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021)
11.10.5 GSK Recent Development
11.11 BIOCAD
11.11.1 BIOCAD Company Details
11.11.2 BIOCAD Business Overview
11.11.3 BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Introduction
11.11.4 BIOCAD Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021)
11.11.5 BIOCAD Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Anti VEGF Drugs
Table 3. Key Players of Photosensitive Drugs
Table 4. Key Players of Others
Table 5. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Regions (2016-2021)
Table 9. Global Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Regions (2022-2027)
Table 11. Age-relatedMacularDegeneration (ARMD) Drugs Market Trends
Table 12. Age-relatedMacularDegeneration (ARMD) Drugs Market Drivers
Table 13. Age-relatedMacularDegeneration (ARMD) Drugs Market Challenges
Table 14. Age-relatedMacularDegeneration (ARMD) Drugs Market Restraints
Table 15. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Players (2016-2021)
Table 17. Global Top Age-relatedMacularDegeneration (ARMD) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Age-relatedMacularDegeneration (ARMD) Drugs as of 2020)
Table 18. Ranking of Global Top Age-relatedMacularDegeneration (ARMD) Drugs Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Age-relatedMacularDegeneration (ARMD) Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Age-relatedMacularDegeneration (ARMD) Drugs Product Solution and Service
Table 22. Date of Enter into Age-relatedMacularDegeneration (ARMD) Drugs Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Type (2016-2021)
Table 26. Global Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Application (2016-2021)
Table 30. Global Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 62. Roche Company Details
Table 63. Roche Business Overview
Table 64. Roche Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 65. Roche Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021) & (US$ Million)
Table 66. Roche Recent Development
Table 67. Regeneron Pharmaceuticals Company Details
Table 68. Regeneron Pharmaceuticals Business Overview
Table 69. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 70. Regeneron Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021) & (US$ Million)
Table 71. Regeneron Pharmaceuticals Recent Development
Table 72. Bayer Company Details
Table 73. Bayer Business Overview
Table 74. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 75. Bayer Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021) & (US$ Million)
Table 76. Bayer Recent Development
Table 77. Santen Oy Company Details
Table 78. Santen Oy Business Overview
Table 79. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 80. Santen Oy Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021) & (US$ Million)
Table 81. Santen Oy Recent Development
Table 82. Kanghong Pharmaceuticals Company Details
Table 83. Kanghong Pharmaceuticals Business Overview
Table 84. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 85. Kanghong Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021) & (US$ Million)
Table 86. Kanghong Pharmaceuticals Recent Development
Table 87. Novartis Company Details
Table 88. Novartis Business Overview
Table 89. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 90. Novartis Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021) & (US$ Million)
Table 91. Novartis Recent Development
Table 92. Eli Lilly and Company Company Details
Table 93. Eli Lilly and Company Business Overview
Table 94. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 95. Eli Lilly and Company Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021) & (US$ Million)
Table 96. Eli Lilly and Company Recent Development
Table 97. TRACON Pharmaceuticals Company Details
Table 98. TRACON Pharmaceuticals Business Overview
Table 99. TRACON Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021) & (US$ Million)
Table 100. TRACON Pharmaceuticals Recent Development
Table 101. Pfizer Company Details
Table 102. Pfizer Business Overview
Table 103. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 104. Pfizer Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021) & (US$ Million)
Table 105. Pfizer Recent Development
Table 106. GSK Company Details
Table 107. GSK Business Overview
Table 108. GSK Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 109. GSK Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021) & (US$ Million)
Table 110. GSK Recent Development
Table 111. BIOCAD Company Details
Table 112. BIOCAD Business Overview
Table 113. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Product
Table 114. BIOCAD Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021) & (US$ Million)
Table 115. BIOCAD Recent Development
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type: 2020 VS 2027
Figure 2. Anti VEGF Drugs Features
Figure 3. Photosensitive Drugs Features
Figure 4. Others Features
Figure 5. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application: 2020 VS 2027
Figure 6. Exudative ARMD Case Studies
Figure 7. Atrophy ARMD Case Studies
Figure 8. Age-relatedMacularDegeneration (ARMD) Drugs Report Years Considered
Figure 9. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Regions: 2020 VS 2027
Figure 12. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Regions (2022-2027)
Figure 13. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Players in 2020
Figure 14. Global Top Age-relatedMacularDegeneration (ARMD) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Age-relatedMacularDegeneration (ARMD) Drugs as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Age-relatedMacularDegeneration (ARMD) Drugs Revenue in 2020
Figure 16. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Type (2016-2021)
Figure 17. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Type (2022-2027)
Figure 18. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type (2016-2027)
Figure 20. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application (2016-2027)
Figure 21. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Country (2016-2027)
Figure 22. United States Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type (2016-2027)
Figure 26. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application (2016-2027)
Figure 27. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Country (2016-2027)
Figure 28. Germany Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Region (2016-2027)
Figure 38. China Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type (2016-2027)
Figure 46. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application (2016-2027)
Figure 47. Latin America Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Country (2016-2027)
Figure 48. Mexico Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Country (2016-2027)
Figure 54. Turkey Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Roche Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021)
Figure 58. Regeneron Pharmaceuticals Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021)
Figure 59. Bayer Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021)
Figure 60. Santen Oy Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021)
Figure 61. Kanghong Pharmaceuticals Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021)
Figure 62. Novartis Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021)
Figure 63. Eli Lilly and Company Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021)
Figure 64. TRACON Pharmaceuticals Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021)
Figure 65. Pfizer Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021)
Figure 66. GSK Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021)
Figure 67. BIOCAD Revenue Growth Rate in Age-relatedMacularDegeneration (ARMD) Drugs Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

---